Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 310.4
(-0.06%)
SEK 310.4
(-0.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 22.12 Billion SEK | 17.74% |
| 2022 | 18.79 Billion SEK | 21.0% |
| 2021 | 15.52 Billion SEK | 1.76% |
| 2020 | 15.26 Billion SEK | 7.11% |
| 2019 | 14.24 Billion SEK | 55.91% |
| 2018 | 9.13 Billion SEK | 40.36% |
| 2017 | 6.51 Billion SEK | 25.1% |
| 2016 | 5.2 Billion SEK | 61.23% |
| 2015 | 3.22 Billion SEK | 23.82% |
| 2014 | 2.6 Billion SEK | 19.77% |
| 2013 | 2.17 Billion SEK | 13.18% |
| 2012 | 1.92 Billion SEK | 0.65% |
| 2011 | 1.91 Billion SEK | 0.22% |
| 2010 | 1.9 Billion SEK | 47.01% |
| 2009 | 1.29 Billion SEK | 13.71% |
| 2008 | 1.14 Billion SEK | -9.22% |
| 2007 | 1.25 Billion SEK | 4.61% |
| 2006 | 1.2 Billion SEK | 28.24% |
| 2005 | 936.61 Million SEK | 45.15% |
| 2004 | 645.28 Million SEK | -61.07% |
| 2003 | 1.65 Billion SEK | 27.33% |
| 2002 | 1.3 Billion SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 6.25 Billion SEK | -8.59% |
| 2024 Q2 | 5.44 Billion SEK | -13.01% |
| 2024 Q3 | 6.89 Billion SEK | 26.68% |
| 2023 Q2 | 4.87 Billion SEK | -7.01% |
| 2023 Q4 | 6.84 Billion SEK | 32.43% |
| 2023 Q3 | 5.16 Billion SEK | 6.08% |
| 2023 Q1 | 5.23 Billion SEK | -12.54% |
| 2023 FY | 22.12 Billion SEK | 17.74% |
| 2022 Q3 | 3.99 Billion SEK | 3.17% |
| 2022 Q4 | 5.99 Billion SEK | 49.79% |
| 2022 Q2 | 3.87 Billion SEK | -21.3% |
| 2022 FY | 18.79 Billion SEK | 21.0% |
| 2022 Q1 | 4.92 Billion SEK | 0.59% |
| 2021 Q1 | 3.66 Billion SEK | -20.08% |
| 2021 Q4 | 4.89 Billion SEK | 30.18% |
| 2021 Q3 | 3.76 Billion SEK | 17.13% |
| 2021 Q2 | 3.21 Billion SEK | -12.29% |
| 2021 FY | 15.52 Billion SEK | 1.76% |
| 2020 Q3 | 2.97 Billion SEK | -3.26% |
| 2020 Q1 | 4.63 Billion SEK | -5.13% |
| 2020 Q2 | 3.07 Billion SEK | -33.82% |
| 2020 FY | 15.26 Billion SEK | 7.11% |
| 2020 Q4 | 4.58 Billion SEK | 54.24% |
| 2019 Q3 | 2.93 Billion SEK | -7.37% |
| 2019 Q4 | 4.89 Billion SEK | 66.89% |
| 2019 FY | 14.24 Billion SEK | 55.91% |
| 2019 Q1 | 3.26 Billion SEK | 27.0% |
| 2019 Q2 | 3.16 Billion SEK | -3.12% |
| 2018 FY | 9.13 Billion SEK | 40.36% |
| 2018 Q3 | 2.31 Billion SEK | 1.14% |
| 2018 Q2 | 2.28 Billion SEK | 16.55% |
| 2018 Q4 | 2.57 Billion SEK | 11.05% |
| 2018 Q1 | 1.96 Billion SEK | 4.76% |
| 2017 FY | 6.51 Billion SEK | 25.1% |
| 2017 Q4 | 1.87 Billion SEK | 17.1% |
| 2017 Q3 | 1.6 Billion SEK | -2.32% |
| 2017 Q2 | 1.63 Billion SEK | 17.41% |
| 2017 Q1 | 1.39 Billion SEK | 8.1% |
| 2016 FY | 5.2 Billion SEK | 61.23% |
| 2016 Q3 | 1.17 Billion SEK | -20.29% |
| 2016 Q1 | 1.27 Billion SEK | 56.41% |
| 2016 Q2 | 1.46 Billion SEK | 15.4% |
| 2016 Q4 | 1.29 Billion SEK | 10.28% |
| 2015 Q3 | 786 Million SEK | 2.88% |
| 2015 FY | 3.22 Billion SEK | 23.82% |
| 2015 Q1 | 865 Million SEK | 22.65% |
| 2015 Q4 | 813.86 Million SEK | 3.55% |
| 2015 Q2 | 764 Million SEK | -11.68% |
| 2014 Q4 | 705.27 Million SEK | 5.91% |
| 2014 FY | 2.6 Billion SEK | 19.77% |
| 2014 Q3 | 665.9 Million SEK | 0.51% |
| 2014 Q2 | 662.5 Million SEK | 15.56% |
| 2014 Q1 | 573.3 Million SEK | -6.12% |
| 2013 Q2 | 520.2 Million SEK | -1.57% |
| 2013 Q1 | 528.5 Million SEK | 12.0% |
| 2013 Q4 | 610.69 Million SEK | 18.05% |
| 2013 FY | 2.17 Billion SEK | 13.18% |
| 2013 Q3 | 517.3 Million SEK | -0.56% |
| 2012 Q3 | 463.8 Million SEK | -3.52% |
| 2012 Q4 | 471.86 Million SEK | 1.74% |
| 2012 FY | 1.92 Billion SEK | 0.65% |
| 2012 Q1 | 506.7 Million SEK | 16.13% |
| 2012 Q2 | 480.7 Million SEK | -5.13% |
| 2011 Q2 | 490 Million SEK | -8.82% |
| 2011 Q3 | 447.1 Million SEK | -8.76% |
| 2011 FY | 1.91 Billion SEK | 0.22% |
| 2011 Q4 | 436.33 Million SEK | -2.41% |
| 2011 Q1 | 537.4 Million SEK | 15.57% |
| 2010 FY | 1.9 Billion SEK | 47.01% |
| 2010 Q1 | 488.1 Million SEK | 40.39% |
| 2010 Q2 | 509.6 Million SEK | 4.4% |
| 2010 Q4 | 465 Million SEK | 4.73% |
| 2010 Q3 | 444 Million SEK | -12.87% |
| 2009 Q3 | 274.2 Million SEK | -14.29% |
| 2009 Q1 | 355.2 Million SEK | 0.0% |
| 2009 Q4 | 347.67 Million SEK | 26.8% |
| 2009 FY | 1.29 Billion SEK | 13.71% |
| 2009 Q2 | 319.9 Million SEK | -9.94% |
| 2008 FY | 1.14 Billion SEK | -9.22% |
| 2007 FY | 1.25 Billion SEK | 4.61% |
| 2006 FY | 1.2 Billion SEK | 28.24% |
| 2005 FY | 936.61 Million SEK | 45.15% |
| 2004 FY | 645.28 Million SEK | -61.07% |
| 2003 FY | 1.65 Billion SEK | 27.33% |
| 2002 FY | 1.3 Billion SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | -1606.433% |
| Enzymatica AB (publ) | 50.9 Million SEK | -43362.203% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | -1629060.53% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | -75339.015% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | -59972.226% |
| ODI Pharma AB | 22.44 Million SEK | -98460.506% |
| Orexo AB (publ) | 638.8 Million SEK | -3363.369% |
| Probi AB (publ) | 627.68 Million SEK | -3424.687% |
| Swedencare AB (publ) | 2.32 Billion SEK | -851.734% |
| Toleranzia AB | 50.92 Million SEK | -43348.547% |
| Vivesto AB | 1.01 Million SEK | -2179604.433% |